Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2972412 | The Journal of Heart and Lung Transplantation | 2008 | 5 Pages |
Abstract
The prevalence of dapsone-induced HA in LT recipients is 5-fold higher than the reported rate in the population of human immunodeficiency virus (HIV) patients. Individuals with renal failure or low body weight and for whom dose exceeds 1.5 mg/kg may be at increased risk for dapsone-induced HA. Although current CDC guidelines do not recommend adjusting dose by IBW or renal function, we suggest that consideration should be given to these dosing strategies.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Priyumvada M. MD, G. Marshall MD, Allan MD, E. Clinton MD, David C. MD, Seth MD, Andres MD,